Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Stock Chart & Stats
$57.77
-$0.14(-8.75%)
At close: 4:00 PM EST
$57.77
-$0.14(-8.75%)
Day’s Range― - ―
52-Week Range$5.67 - $57.86
Previous CloseN/A
Volume421.15K
Average Volume (3M)3.00M
Market Cap
$1.60B
Enterprise Value$919.71M
Total Cash (Recent Filing)$157.34M
Total Debt (Recent Filing)$2.60M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Mar 05, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding27,710,870
10 Day Avg. Volume4,570,701
30 Day Avg. Volume3,002,430
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.60K
Enterprise Value/Ebitda-8.52
Forecast
1Y Price Target
$58.00Price Target Upside0.40% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2 head‑to‑head data in chronic spontaneous urticaria demonstrated numerically higher response rates and a clean safety profile versus the established therapy, supporting advancement into pivotal testing.
Commercial StrategyGSK's acquisition provides global development and commercialization resources and access to a broad allergy prescriber base, improving the prospects for a successful market launch upon approval.
Therapeutic ProfileAnalysts note ozureprubart's extended half‑life and stronger IgE suppression could enable less frequent injections and allow treatment of patients who are ineligible for the incumbent therapy.
Bears Say
Clinical Readout UncertaintyA smaller asthma readout is not powered for efficacy and may be less informative, leaving uncertainty about the therapy's broader respiratory benefit.
Deal Economics And Investor ReactionThe acquisition structure cedes rights in certain Asian territories and involves milestone and royalty payments, which could limit upside and prompt analyst downgrades that weigh on the stock.
Regulatory And Development RiskAdvancement into pivotal Phase 3 depends on positive trial outcomes and regulatory alignment, creating execution and approval risk that could delay or derail the development plan.
RAPT Therapeutics News
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $5.67 and its highest was $57.86 in the past 12 months.
What is RAPT Therapeutics’s market cap?
RAPT Therapeutics’s market cap is $1.60B.
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 20 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.978 by $0.328.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -0.83.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 27,710,870 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.978. Following the earnings report the stock price went up 2.724%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Currently, no hedge funds are holding shares in RAPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RAPT Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$58.00 (0.40% Upside)
$58.00 (0.40% Upside)
Blogger Sentiment
Bullish
RAPT Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
522.52%
12-Months-Change
Fundamentals
Return on Equity
-85.37%
Trailing 12-Months
Asset Growth
52.80%
Trailing 12-Months
Company Description
RAPT Therapeutics
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Stock 12 Month Forecast
Average Price Target
$58.00
▲(0.40% Upside)
Technical Analysis
Neurogene
―
DBV Technologies SA - American
―
Autolus Therapeutics
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
2.04% Insiders
3.23% Mutual Funds
42.32% Other Institutional Investors
45.22% Public Companies and
Individual Investors